World Congress of Cardiology: DES Safety Dominates Discussions
While the greater efficacy of drug-eluting stents (DES) compared to bare-metal stents is widely accepted, over the past year, data has continued to build showing that first-generation DES also have a higher late-stage in-stent thrombosis risk, a complication that can cause death 30% of the time, according to some estimates. The findings of these studies had some physicians at this year's World Congress of Cardiology calling for "an immediate halt to DES overuse." However, most conceded that additional randomized trials will be needed to fully understand the potential risks associated with these devices.
You may also be interested in...
At TCT, DES Use and Safety Concerns: Irrational Exuberance or Irrational Anxiety?
Still feeling the reverberations of data released in Barcelona in September, this year's TCT meeting saw session after session on the risks of stent thrombosis from drug-eluting stents. While the data was clear--there is some risk, but not a lot--what to do about it was less clear. And the whole debate raises more questions than answers, for both interventionalists and cardiovascular device companies.
Medtronic Licenses Early Stage Stent Drug to Prevent Thrombosis
Medtronic has gained rights to ReVas, a drug development program based on novel targets of vascular inflammation, from Resverlogix, for use with drug-eluting stents to prevent thrombosis.
What's Hot in Cardiology beyond DES? Try Structural Heart Disease
Structural heart disease was prominently featured during the Emerging Technologies Symposium held during this year's Summer in Seattle cardiovascular conference.